Please login to the form below

Not currently logged in
Email:
Password:

Vectibix

This page shows the latest Vectibix news and features for those working in and with pharma, biotech and healthcare.

Takeda hands back rights to two Amgen drugs

Takeda hands back rights to two Amgen drugs

The two companies have already worked together to bring Amgen's fast-growing colorectal cancer therapy Vectibix (panitumumab) to the Japanese pharma market, the second-largest in the world.

Latest news

More from news
Approximately 3 fully matching, plus 18 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Dr Reddy's has expanded its collaboration with Amgen in India adding three approved products: Xgeva for treating bone metastases, Vectibix in colorectal cancer therapy and Prolia for osteoporosis.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Random42 Scientific Communication

    The Telly Awards - A Biotech Pioneer. 2011 – Silver. Davey Awards - Vectibix. ... 2011 – Gold. Communicator Awards – Vectibix. 2011 – Gold. Communicator Awards – Systane Balance.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics